LipoCurc™
Glioblastoma (First-line treatment)
Phase 2Active
Key Facts
About Signpath Pharma
Signpath Pharma is a private, clinical-stage biotech leveraging its patented CorreQT platform to develop cardiac-safe drugs. Its primary focus is mitigating the cardiotoxicity associated with chemotherapies and other drug classes. The company's most advanced asset, LipoCurc™, has completed Phase 1 trials and is now in a Phase 2 study for glioblastoma, while its platform technology is being applied to create new compounds like SPP4040. With leadership experienced in biotech and cardiology, Signpath is targeting significant unmet needs in oncology supportive care and broader drug safety.
View full company profile